Health News

Asthma Relief: All in the Head?
Could it be mind over matter? Getting relief from many asthma symptoms may be as simple as believing you are taking a treatment that will help.
Double-Whammy during Pregnancy
Being obese can make pregnancy harder than it already is. Adding type 2 diabetes to that mix makes pregnancy risky for both the mother and the baby.
Foodborne Outbreak Potentially Associated With Papaya
The FDA is warning consumers not to eat papayas from Agromod Produce, Inc., a distributor in McAllen,Texas.
Single Brain Injury May Lead to Neurodegeneration
Traumatic brain injuries are known to be a risk factor for later development of cognitive impairments. Recent findings suggest that even a singular brain injury could lead to diminished neurological capacity.
The Protective Effects of Estrogen
Estrogen has been getting a bad name lately. The female hormone drives the most common form of breast cancer, but a new study suggests it also protects women from other types of cancer.
FDA Drug Safety Communication: Letairis
The U.S. Food and Drug Administration (FDA) is removing the warning related to liver injury from the boxed warning of the Letairis ( ambrisentan ) tablet label.
FDA Drug Safety Communication: Pradaxa
The U.S. Food and Drug Administration (FDA) is alerting the public to important storage and handling requirements for Pradaxa ( dabigatran etexilate mesylate ) capsules.
FDA Drug Safety Communication: Benicar
After reviewing the results of the ROADMAP and ORIENT trials, the FDA has determined that the benefits of Benicar continue to outweigh its potential risks when used for the treatment of patients with high blood pressure according to the drug label. Benicar is not recommended as a treatment to delay or prevent protein in the urine ( microalbuminuria ) in diabetic patients. Patients should consult their healthcare professional if they have any questions or concerns about taking Benicar . Daiichi Sankyo , the makers of Benicar , have agreed to work with the FDA to perform additional ...
FDA Drug Safety Communication: Revlimid
The U.S. Food and Drug Administration (FDA) is informing the public that we are aware of results from clinical trials conducted inside and outside the United States that found that patients treated with Revlimid ( lenalidomide ) may be at an increased risk of developing new types of cancer compared to patients who did not take the drug. FDA is currently reviewing all available information on this potential risk and will communicate any new recommendations once it has completed its review. At this time, FDA recommends that patients continue their Revlimid treatment as prescribed by their...
FDA Drug Safety Communication: TNF blockers
The U.S. Food and Drug Administration (FDA) is informing the public that it continues to receive reports of a rare cancer of white blood cells (known as h epatosplenic T-Cell lymphoma or HSTCL ), primarily in adolescents and young adults being treated for Crohn’s disease and ulcerative colitis with medicines known as tumor necrosis factor ( TNF ) blockers, as well as with azathioprine , and/or mercaptopurine . Crohn's disease and ulcerative colitis cause inflammation of the digestive system. Common symptoms are pain in the abdomen, cramps, and diarrhea. Bleeding from the rectum, wei...
<< first147714781479148014811482148314841485last >>

REFINE